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Angiogenesis contributes to the development of
numerous disorders. Even though fibroblast growth
factors (FGFs)werediscoveredasmediatorsofangio-
genesis more than 30 years ago, their role in develop-
mental angiogenesis still remains elusive. We use
a recently described chemical probe, SSR128129E
(SSR), that selectively inhibits the action of multiple
FGF receptors (FGFRs), in combination with the
zebrafish model to examine the role of FGF signaling
in vascular development. We observe that while
FGFR signaling is less important for vessel guidance,
it affects vascular outgrowth and is especially
required for the maintenance of blood vessel integrity
by ensuring proper cell-cell junctions between endo-
thelial cells. In conclusion, our work illustrates the po-
wer of a small molecule probe to reveal insights into
blood vessel formation and stabilization and thus of
broad interest to the vascular biology community.
INTRODUCTION
The recent success of antiangiogenic vascular endothelial
growth factor (VEGF)-targeted agents for the treatment of cancer
and ocular disease highlights their therapeutic potential (Craw-
ford and Ferrara, 2009; Potente et al., 2011). Nonetheless,
intrinsic refractoriness (a phenomenon describing the lack of
response from the onset of treatment) and acquired resistance
limit their success (Bellou et al., 2013). Delivery of additional anti-
angiogenic agents with a complementary mechanism might
maximize the efficacy and minimize the resistance to available
antiangiogenic agents.
Substantial efforts have been invested to develop low molec-
ular weight chemical compounds, inhibiting the activity of growth
factor receptor tyrosine kinases (RTKs) (Lemmon and Schles-
singer, 2010). However, these compounds must cross the
plasmamembrane, as the tyrosine kinase (TK) domain is located
intracellularly. In addition, since the structure of the TK domain is1310 Chemistry & Biology 21, 1310–1317, October 23, 2014 ª2014 Ehighly conserved, most of these compounds inhibit multiple
related kinases (Fabian et al., 2005), which increases the risk of
adverse effects (Jain et al., 2006).
As most current antiangiogenic agents inhibit VEGF signaling
(Bellou et al., 2013; Ferrara and Kerbel, 2005; Jain et al., 2006;
Jeltsch et al., 2013), we explored whether inhibition of another
angiogenic growth factor (family) might be of therapeutic value.
Fibroblast growth factors (FGFs) and their receptors (FGFRs)
stimulate angiogenesis (Saylor et al., 2012). Importantly,
compensatory upregulation of FGFs in tumor-bearing mice,
treatedwith VEGF inhibitors, contributes to tumor relapse (Bellou
et al., 2013; Casanovas et al., 2005). FGFR signaling has also
been implicated in human cancer, arthritis, and ocular disease
(Liang et al., 2013; Malemud, 2007). The FGF superfamily con-
sists of at least 23 distinct structurally related FGFs, each binding
one or more of the four high-affinity RTKs (Itoh and Ornitz, 2011).
Only a few reports have documented the role of endogenous
FGFs in vascular development (Lavine et al., 2006; Murakami
et al., 2008), and these studies have been donemostly in cultured
embryos (Lee et al., 2000; Ribatti and Presta, 2002).
We recently reported the identificationofSSR128129E (‘‘SSR’’),
an orally administrable, allosteric multi-FGFR blocker that is
capable of inhibiting FGFR signaling in a wide spectrum of
distinct species ranging from the silkworm, moth, fruitfly, zebra-
fish, tadpole,mouse,andpig tohumans (Bonoetal., 2013;Herbert
etal., 2013).Thiscompoundspecifically inhibitsFGF-inducedpro-
liferation,migration, and survival of endothelial cells (ECs), without
affecting signaling by unrelated RTKs that bind VEGF, platelet-
derived growth factor-B (PDGF-B), hepatocyte growth factor
(HGF), or other ligands (Bono et al., 2013). In addition, the FGFR
selectivity of SSRwas further confirmedbyfindings that treatment
of zebrafish embryos with SSR evoked the same phenotypic ef-
fects as silencing of critical FGFRs without inducing additional
off-target effects (Bono et al., 2013). Notably, the sequence ho-
mologyof theputativeSSRbinding site is highly conserved across
various species (Bono et al., 2013; Herbert et al., 2013).
When used in vivo, this compound inhibits blood vessel for-
mation in malignant and inflammatory diseases in mice, without
causing overt systemic effects (Bono et al., 2013). However, the
effect on developmental angiogenesis was not studied. The
availability of SSR as a novel tool allowed us to investigatelsevier Ltd All rights reserved
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Figure 1. FGFR Expression in Zebrafish Embryos
(A and B) Endothelial expression of FGFRs was determined by real-time RT-PCR analysis of GFP+ ECs isolated by flow cytometry from 24 hpf Tg(fli1:EGFP)y1 and
Tg(flk1:EGFP) zebrafish embryos. Data are mean ± SEM.
(C–F) Whole-mount in situ hybridization of 24 hpf embryos revealed that fgfr1 and fgfr2were expressed in the DA, PCV, intersegmental vessels (ISVs; arrows) and
vascular plexus (VP) in the ventrocaudal tail, while expression of fgfr3 in these vessels was less pronounced. The inset in C and D displays a higher magnification
of the fgfr1- and fgfr2-positive ISVs (red boxed ares). Fgfr3 and fgfr4 are both present in the vascular plexus (VP), while fgfr3 is faintly expressed in the DA, and
fgfr4 is expressed in the caudal somites. Fgfr4 was mainly present in the vacular plexus at 24 hpf. Scale bars denote 100 mm in (C)–(F).
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Role for FGF Signaling in Blood Vessel Maintenancethe role of FGF signaling in vascular development in more detail.
Here, we report, using the small animal zebrafish model, that the
inhibition of FGF signaling by SSR affects blood vessel formation
by interfering with vessel stabilization and to some extent also
vessel sprouting.
RESULTS
Expression of FGFRs in Zebrafish Vessels
We first studied the expression pattern of FGFRs in zebrafish
embryos at different stages of development. Endothelial expres-
sion of the FGFRs was confirmed by reverse transcription-
polymerase chain reaction (RT-PCR) analysis of GFP+ ECs
isolated by flow cytometry from 24 hr postfertilization (hpf)
Tg(fli1:EGFP)y1 and Tg(flk1:EGFP) zebrafish embryos (Chitten-
den et al., 2006; Jin et al., 2005; Lawson and Weinstein, 2002)
(Figures 1A and 1B). Whole-mount in situ hybridization of
24 hpf embryos revealed that fgfr1 and fgfr2 were expressed in
the dorsal aorta (DA), posterior cardinal vein (PCV), and vascular
plexus in the ventrocaudal tail (Figures 1C and 1D), while expres-
sion of fgfr3 and fgfr4was less pronounced in these vessels (Fig-
ures 1E and 1F). Fgfr1 and fgfr2 were also detectable in
intersomitic vessels (ISVs). By 28 hpf, expression of fgfr1 and
fgfr2 in the vasculature was reduced, while fgfr3 expression
remained similar (data not shown).
Uptake of SSR in Zebrafish Embryos
We then assessed the uptake of SSR by zebrafish embryos after
supplementing the compound to the swimming water. Since up-
take codetermines tissue levels of SSR and pharmacokinetics
differ in animal models, we developed an analytical high-perfor-
mance liquid chromatography (HPLC) method to quantify theChemistry & Biology 21, 1310–1amount of SSR in zebrafish extracts (Bono et al., 2013). Expo-
sure of zebrafish from 20 to 44 hpf to SSR in the swimming water
at concentrations used to study its effect on vascular develop-
ment (from 10 to 200 mM; see below) resulted in tissue levels of
SSR ranging from 0.4 to 3.9 mg/mg protein (corresponding to
an estimated tissue concentration range from 5 to 47 mM in
the zebrafish embryo of which approximately 2% is bioavailable;
Table S1 available online).
SSR Impairs Angiogenesis in Zebrafish
To evaluate the effect of SSR on ISV development, we supple-
mented the compound to the water tank of zebrafish embryos,
but only from 20 hpf onward for two reasons: first, this is the
stage when ISVs sprout from the DA and navigate dorsally
alongside a stereotypic trajectory to form the dorsal longitudinal
anastomosing vessel (DLAV) by 28 hpf, and second, we wished
to bypass effects of this chemical on early embryonic develop-
ment, which might secondarily cause vessel defects. Indeed,
SSR treatment of very early embryos caused secondary gastru-
lation defects (Bono et al., 2013). Only embryos with no or at
most a minimal growth delay were analyzed.
Macroscopic inspection revealed that SSR-treated embryos
had a slightly shorter tail and developed edema in the pericardial
region and ventrocaudal portion of the tail beyond 2 days post-
fertilization (dpf) (data not shown). At 24 hpf, blood flow was
detectable in axial vessels, but was shunted through abnormal
connections between the DA and PCV. This phenotype was
not due to loss of arteriovenous specification, as in situ hybridi-
zation for the arterial marker ephrin-B2 and the venous marker
dab2 after treatment with SSR from 20 hpf for 8 hr did not reveal
any differences in their expression pattern (Figures S1A–S1D).
By 48 hpf, flow through the ISVs in SSR-treated embryos was317, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1311
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Figure 2. SSR Interferes with Blood Vessel
Formation in Zebrafish
Two-photon confocal images of GFP+ vessels in
the trunk of Tg(fli1:EGFP)y1 zebrafish embryos at
26 hpf (A, C, E, and G) or 45 hpf (B, D, F, H, and I)
after exposure to DMSO as control (A and B) or
increasing concentrations of SSR in the swimming
water (C–I). The DA, PCV, intersegmental vessels
(ISVs), and DLAV are indicated. At 26 hpf, SSR did
not prevent sprouting of the ISVs at their desig-
nated branch sites; neither did it cause misrouting
or erroneous navigation of ISVs from their stereo-
typed ventrodorsal trajectory (A, C, E, and G). At
100 and 200 mMSSR in the swimmingwater (tissue
concentration 3.1 and 3.9 mg/mg protein, respec-
tively), the ISVs started to show the first signs of
vessel collapse (E and G). By 45 hpf, the ISVs in
control embryos had reached the dorsal roof and
branched into a DLAV (B). In contrast, SSR dose
dependently caused disintegration of the ISVs and
DLAV, with ECs rounding up, becoming detached
from each other and residing as single ghost cells
(arrowheads in I), that ultimately disappeared (data
not shown). In a subpopulation, the ISVs stalled
midway their trajectory after exposure to 200 mM
SSR (tissue concentration 3.9 mg SSR/mg protein),
indicating a partial inhibition of vessel sprouting
(H). In all panels, the head of the embryo faces left,
and scale bars denote 50 mm. See also Figure S1,
Table S1, and Movies S1 and S2.
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Role for FGF Signaling in Blood Vessel Maintenanceeither sluggish or entirely absent. Other FGF-dependent devel-
opmental processes (somitogenesis, hematopoiesis) were not
overtly affected, likely because they were already largely
completed before the embryos were exposed to the compound
(Figure S1E–S1J). SSR-treated embryos eventually succumbed
to their vascular defects beyond 2 or 3 dpf when exposed
to the highest or intermediate doses, respectively. Tissue SSR
levels were 3.9 mg/mg for the highest concentration of SSR
in the swimming water (200 mM) and 1.9 and 3.1 mg/mg for the
intermediate dose of SSR (50–100 mM), respectively.
Vascular Defects in SSR-Treated Zebrafish Embryos
The nature of these vascular defects was further analyzed
in Tg(Fli1:EGFP)y1 zebrafish embryos. In control embryos, ISVs1312 Chemistry & Biology 21, 1310–1317, October 23, 2014 ª2014 Elsevier Ltd All rights resbranched off by 20 hpf at designated
branch sites into the intersomitic bound-
aries and navigated, alongside a stereo-
typed ventrodorsal trajectory in between
the somites, notochord, and neural tube
to the dorsolateral roof of the neural
tube (Figure 2A). By 45 hpf, the most
dorsally positioned endothelial tip cell
had split into the anterior and posterior
direction to establish, via fusion with adja-
cent ECs, the DLAV (Figure 2B). At inter-
mediate concentrations of SSR in the
swimming water (50–100 mM, resulting in
SSR tissue levels of 1.9 to 3.1 mg/mg),
the ISVs still reached the dorsal roof and
navigated alongside their stereotyped tra-jectory (Figures 2C–2F). The dorsalmost EC also branched nor-
mally into a DLAV (Figure 1D). However, by 45 hpf, the ISVs,
DLAV, and other vessels all started to disassemble. Indeed, in
SSR-treated embryos, individual ECs in ISVs detached from
adjacent cells, rounded up, became disconnected from each
other, resulting in ISVs with an irregular shape and size, often
with a thin, slender lumen—explaining why these ISVs were
not perfused any longer (Figures 2D and 2F; Movies S1 and S2).
At the highest dose of SSR (200 mM in the swimming water,
resulting in SSR tissue levels of 3.9 mg/mg protein), sprouting of
ISVswasdelayedbyapproximately1 to2hr,even though ISVsstill
branched off at their designated branch sites. By 26 hpf, the ISVs
had navigated midway along their correct ventrodorsal trajectory
(Figure 2G). However, thereafter, in up to 25%of the SSR-treatederved
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Figure 3. Inhibition of FGFRs Results in Reduced VE-Cadherin Junctions
Immunostaining of whole-mount zebrafish embryos for VE-cadherin (A and D, or red in C and F), showing intact and continuous EC-cell contacts in control-treated
Tg(fli1:EGFP)y1zebrafishembryosat49hpf (A–C),whileSSR-treatedzebrafish (exposure to75mMin theswimmingwater; tissueconcentration2.4mgSSR/mgprotein)
(D–F) had a discontinuous VE-cadherin lining with reduced VE-cadherin-positive EC-cell juctions, explaining why ECs became disconnected from each other.
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Role for FGF Signaling in Blood Vessel Maintenanceembryos, the ISVs stalled and failed to reach the dorsal roof, even
not by 45 hpf (Figure 2H). In the other 75% of SSR-treated em-
bryos, the ISVs reached the dorsal roof and branched into a
DLAV, but strikingly these newly formed vessels started to disin-
tegrate entirely, with the residual ECs becoming disconnected
isolated ghost cells (Figure 2I). Similar findings were obtained
when using NVP-BGJ398, a more selective TK inhibitor of
FGFR1/2/3 (Figures S1K–S1N), further confirming that SSR
induced these vascular defects by inhibiting FGFR signaling.
The aforementioned results indicate that FGF signaling was
essential for the maintenance of vascular integrity. To further
study the mechanism of disassembly of the DLAV, we stained
whole-mount embryos for the junctional molecule VE-cadherin,
since an earlier study documented that FGFR signaling is essen-
tial for the maintenance of the integrity of the endothelial layer
by stabilizing VE-cadherin junctions (Murakami et al., 2008).
This analysis revealed that the VE-cadherin-positive EC lining
of the ISVs and forming DLAV was interrupted and that VE-cad-
herin-positive cell-cell junctions between ECs were substantially
reduced in SSR-treated embryos as compared to control
embryos, explaining why SSR-treated embryos did not establish
or maintain stable cell-cell connections (Figure 3).
SSR also impaired the branching of the venous plexus in
the tail and the outgrowth of the subintestinal vessels (Figures
4A–4D). A previous study reported that FGFR signaling affects
vascular development by upregulation of VEGF expression (Mur-
akami et al., 2011). However, RT-PCR analysis of 46 hpf embryos
did not reveal any significant differences between SSR-treatedChemistry & Biology 21, 1310–1(75 mM in the swimming water, corresponding to a tissue con-
centration of 2.4 mg/mg) and control embryos (mRNA copies
vegf per 103 mRNA copies gapdh 0.18 ± 0.01 in control versus
0.25 ± 0.05 in SSR-treated fish; N = 5; p = 0.13). Thus, inhibition
of FGF signaling in zebrafish embryos not only aborted the devel-
opment of new vessels, but also caused vessel collapse, without
disturbing vessel navigation.
SSR Impairs Vessel Outgrowth in Adult Wound Healing
We also analyzed whether SSR inhibited angiogenesis during
adult fin regeneration, amodel of angiogenesis in healingwounds
(Bayliss et al., 2006). The caudal fin in adult zebrafish consists of
parallel bony rays, each containing a central artery and two adja-
cent veins with interconnecting intraray vessels, which can be
readily visualized in Tg(fli1:EGFP)y1 zebrafish. Upon amputation
of the fin, new capillaries sprout from the residual vessels, form
a primitive vascular plexus, which subsequently remodels into
an extendedmature vascular bed of a single artery and two veins
per raywithin 8 days after amputation (Figures 5A and5B) (Huang
et al., 2003). Unlike bone and other cell types, ECs do not differ-
entiate from the blastema (a cluster of progenitor cells in the
regenerating fin tip), but directly sprout from existing vessels,
thus reflecting true angiogenesis (Huang et al., 2003). Immedi-
ately after caudal fin amputation, the adult fish were exposed
to 200 mM SSR, and regenerative angiogenesis was monitored
over 7 days. Macroscopic inspection complemented with
morphometric quantification of the GFP+ vessel area in the re-
generating fin revealed that SSR inhibited angiogenic sprouting317, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1313
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Figure 4. Role of FGFs in Other Angiogenesis Processes in Zebra-
fish
(A and B) Fluorescent images (ventral view) of GFP+ subintestinal vessels
(SIVs) on the surface of the yolk sac of 72 hpf Tg(fli1:EGFP)y1 zebrafish em-
bryos, revealing normal SIVs after exposure to DMSO (A) and severe under-
development of these SIVs after exposure to 50 mMSSR (tissue concentration
1.9 mg SSR/mg protein) from 20 hpf onward (arrowheads in B).
(C and D) Images (lateral view) of the GFP+ vascular plexus (VP) in the posterior
trunk of 45 hpf Tg(fli1:EGFP)y1 zebrafish embryos. In DMSO treated control
embryos (C), a vascular plexus formed via branching from the caudal vein. After
exposure to 200 mM SSR (tissue concentration 3.9 mg SSR/mg protein) from
20 hpfs onward, the vascular plexus failed to remodel and branch and, instead,
only a large vascular syncytium was formed (D). In all panels, the head of the
embryo faces left; scalebarsdenote50mmin (A) and (B) and100mmin (C)and (D).
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Role for FGF Signaling in Blood Vessel Maintenanceby 40% (Figures 5A–5C). As expected, considering the impor-
tance of FGF signaling in tissue regrowth, regeneration of the
fin itself was also impairedby 33%bySSR (Figure 5D). Thedefect
of fin regeneration coincided with that of vessel regrowth. Even
though FGF signaling plays a key role in fin regeneration (Poss
et al., 2000), previous findings that selective angiogenesis
blockade impairs fin regeneration (Bayliss et al., 2006)might sug-
gest thatSSR restricts fin regeneration at least in part by inhibiting
angiogenesis. Thus, SSR inhibited vessel growth during develop-
ment in embryos and regeneration in adults.
DISCUSSION
The availability of SSR as a novel pharmacological tool to inhibit
broad FGFR signaling offered us the opportunity to characterize
the role and importance of the endogenous FGF/FGFR family
in vascular development. This could not be studied previously,
since loss of Fgfr1 or Fgfr2 in mice or overexpression of a domi-
nant-negative Fgfr in frogs causes embryonic death before onset
of vessel formation, while mice, zebrafish, or tadpoles lacking
Fgfr3 or Fgfr4 or some of the FGFs do not exhibit vessel defects
(Arman et al., 1998; Miller et al., 2000; Reifers et al., 2000; Zhou
et al., 1998). Even though delivery of Fgf proteins or their genes
encoding such proteins stimulates angioblast migration and
vessel development in avian embryos (Javerzat et al., 2002; Rib-
atti and Presta, 2002), the endogenous role of FGF signaling in
vascular development in the embryo still remained incompletely
determined. Only a few publications have thus far documented a
role for FGFs in vascular development. Topical application of an1314 Chemistry & Biology 21, 1310–1317, October 23, 2014 ª2014 Eanti-FGF2 antibody caused an avascular area in the chicken
allantois membrane (Ribatti and Presta, 2002), while injection
of an adenoviral vector encoding a dominant-negative FGFR1
transgene disrupted vascular integrity in cultured mouse em-
bryos (Lee et al., 2000). Also, combined inactivation of FGFR1
and FGFR2 in ECs impaired coronary vessel formation (Lavine
et al., 2006), while administration of soluble FGFRs to adult
mice showed, similar to our observations, a loss of vascular
integrity (Murakami et al., 2008).
While valuable, these studies did not offer the opportunity
to perform a kinetic dose-dependent analysis of the role of
(other) FGFs in vascular development within a living embryo by
using high-resolution imaging, which is required to unveil, for
instance, abnormalities in vessel navigation. In addition, others
suggested that cultures may introduce bias because of mis-
regulated gene expression or exogenous factors added to the
cultures (Lee et al., 2000). Another outstanding question was
whether FGFs, known to determine tissue patterning asmorpho-
genic signals and to regulate the expression of axon and vessel
guidance signals (Charron and Tessier-Lavigne, 2005; Hausott
et al., 2011; Tole et al., 2006), would determine vessel navigation.
By conditionally exposing zebrafish embryos to a dose range
of the allosteric multi-FGFR inhibitor SSR at a postgastrulation
stage, we obtained the following insights. First, FGFs regulate
vessel sprouting—administration of SSRafter onset of ISV forma-
tion caused these vessels to stall in zebrafish embryos. The role of
FGF signaling in vessel sprouting is consistent with previous find-
ings of these factors in other systems (Bashamet al., 2013; Ghab-
rial et al., 2003; Hausott et al., 2011; Lee et al., 2000; Sekine et al.,
1999; Szebenyi et al., 2001). Second, FGFs are not required for
the stereotypic spatiotemporal guidance of ISVs alongside their
dorsal trajectory. Third, once established, vessels require contin-
uous FGF signals for maintenance of their structural integrity. The
reason why SSR caused vascular defects in zebrafish embryos,
while loss of FGF1 and FGF2 did not result in similar defects
in mouse embryos (Arman et al., 1998; Zhou et al., 1998), likely
relates to SSR’s activity to inhibit multilple FGFR subtypes and
isoforms simultaneously. Overall, our pharmacological studies
in the small aquatic animal model revealed conceptual insights
in the mechanistic role of FGFs in vascular development.
While the vascular biology community has focused in the last
decade primarily on understanding the molecular basis of the for-
mation of new vessels, the stabilization of newly formed vessels
and their maintenance have received less attention. It has been
postulated that FGF signaling is required for stimulating ECbarrier
tightening by affecting the formation of tight junctions by VE-cad-
herin and other junctional proteins (Bendfeldt et al., 2007; Hata-
naka et al., 2012; Murakami et al., 2008). Our findings are consis-
tent with these observations and illustrate the importance of
FGFRsignaling inmaintaining the integrity of the endothelial lining.
In conclusion, our study provides an example of how a new
chemical reagent (the small molecule SSR, a chemical multi-
FGFR inhibitor) can be used to provide unique insight into the
biological process of vessel formation and stabilization.
SIGNIFICANCE
Angiogenesis or blood vessel growth contributes to the
development of numerous disorders. Even though FGFslsevier Ltd All rights reserved
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Figure 5. Inhibition of FGFRs during Fin
Regeneration in Adult Zebrafish
(A and B) GFP+ vessels in the fin of adult
Tg(fli1:EGFP)y1 zebrafish at 7 days after amputation
(dpa) of the ventral fin. The amputation line is indi-
cated by a white dotted line. Note the impaired
vessel regeneration in the SSR-treated fish (B). The
white double arrow denotes the outgrowth length
of the new blood vessels in the regenerated fin.
(C and D) Morphometric quantification of the GFP+
vessel area (C) or the overall tissue (D) in the re-
generating fin of adult Tg(fli1:EGFP)y1 zebrafish,
showing that SSR inhibited vessel regeneration by
40% and tissue regrowth by 33% (data are mean ±
SEM. N = 7 per group; p < 0.01 by ANOVA repeated
measurements. *p < 0.05 versus control at each
time point by t test). Scale bars denote 250 mm in (A)
and (B).
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Role for FGF Signaling in Blood Vessel Maintenancewere discovered asmediators of angiogenesis more than 30
years ago, their role in developmental angiogenesis still re-
mains elusive. Using a chemical compound (SSR128129E)
that selectively inhibits the action of multiple FGFRs, we
report here that, using the zebrafish model, FGFR signaling
is essential for vascular development. While FGFR signaling
is less important for vessel guidance, it affects vascular
outgrowth and is especially required for the maintenance
of blood vessel integrity by ensuring proper cell-cell con-
tacts between ECs.Chemistry & Biology 21, 1310–1317, October 23, 2014EXPERIMENTAL PROCEDURES
Zebrafish Model of Angiogenesis
Tg(fli1:EGFP)y1 zebrafish (Lawson and Weinstein,
2002) and Tg(flk1:EGFP) (Jin et al., 2005) were
maintained under standard laboratory conditions.
Embryos of 20 hpf were dechorionated by trypsini-
zation (Sigma, 1.5 mg/ml in PBS) and immediately
incubated in 0.33 Danieau containing the melano-
genesis inhibitor 1-phenyl-2-thiourea (PTU, to pre-
vent pigmentation initiation) and supplemented
with SSR (supplied by Sanofi-Aventis, Toulouse, or
NVP-BGJ398) (Selleckchem) at the indicated doses.
Between 30 and 60 embryos were analyzed per
experiment to identify alterations in sprouting of
intersegmental vessels of the trunk region, and
each experiment was repeated five times. Com-
pound/DMSO and growth medium were refreshed
daily. The penetrance of the phenotype was scored
by counting the affected embryos (expressed in %
of embryos analyzed). For time-lapse movies,
zebrafish embryos were immobilized in low melting
agarose and anesthesized in tricaine. Images
and time-lapse movies were obtained with a Zeiss
CLSM510 NLO META mounted on an AxioVert
200M (Zeiss, Sliedrecht) inverted microscope.
Two-photon imaging of EGFP was performed using
920 nm pulsed mode-locked laser emission from
a tunable Ti:Sapphire Chameleon laser (Coherent).
Whole-mount in situ hybridization was performed
on dechorionated embryos that were fixed over-
night in 4% paraformaldehyde at 4C as
described (Chittenden et al., 2006). Probes for all
FGFRs were generated with the following primers
(fgfr1for 50-gctttgctcagggactcaac-30, fgfr1rev 50-
tcacctcgatgtgtttcagc-30, fgfr2for 50-tgacctggtgtcagagatgg-30, fgfr2rev 50-cca
cattaaaaccccaaacg-30, fgfr3for 50-taccgaggacaacgtgatga-30, fgfr3rev 50-
cggacaggtcggtgaatact-30, fgfr4for 50-tttcaaccaccccagtttgt-30, fgfr4rev 50-
tggaatgtcatgtggttcgt-30). Probes for ephrinB2a, dab2, myoD, gata1, and
cmlc2 were used as previously described (Chittenden et al., 2006; Geudens
et al., 2010). VE-cadherin staining was performed as previously described
(Blum et al., 2008).
Adult Zebrafish Fin Regeneration
The adult fin regeneration assay was performed as described (Bayliss et al.,
2006). Briefly, ventral caudal zebrafish fins were amputated at midfin level.ª2014 Elsevier Ltd All rights reserved 1315
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Role for FGF Signaling in Blood Vessel MaintenanceImmediately thereafter, zebrafish were transferred to fish water at 31C–33C,
with a 14 hr light/10 hr dark cycle. Up to seven adult zebrafish of 16 weeks
of age were placed in 1-l tanks containing 750 ml fish water, supplemented
with DMSO (Sigma) for controls, or with SSR (200 mM dissolved in DMSO).
Compound/DMSO and tank water were refreshed daily. Similar nontoxic con-
centrations of DMSO (maximally 0.1%) were always used for both controls
and SSR-treated fish. New vessel formation in the regenerating fin was quanti-
fiedmorphometrically by using theKS300 software (Zeiss) tomeasure theGFP+
area (mm2) in four fin rays, caudal to the amputation line, on micrographs (503
magnification) taken by a Zeiss SteREO Lumar V.12 stereomicroscope equip-
ped with an AxioCam MrC5 (Zeiss) digital camera and AxioVision 4.4 software
(Zeiss). The regenerating vessel area wasmeasured daily for a period of 7 days.
Flow Cytometry
The tails of dechorionated zebrafish embryos were triturated by pipetting in ice-
cold 0.93Dulbecco’s PBS containing 2% fetal bovine serum (FBS), spun down
and treated with 0.25% trypsin solution (GIBCO) at 28C. The suspension was
pipetted up and down regularly until reaching the single cell state, upon which
the trypsin was inactivated by adding FBS. The suspension was subsequently
passed twice through a 40 mm cell strainer, spun down to collect all cells, and
resuspended to a density of about 106 cells/ml. Cell sorting was subsequently
done on a FACS Calibur (BD Biosciences) system by sorting GFP+ cells. Gating
was optimized by preparing cell suspensions of nontransgenic zebrafish.
Quantitative Real-Time RT-PCR
Total RNAwas isolated using the Trizol reagent (Invitrogen) and the RNeasy Kit
(QIAGEN), from which cDNA was subsequently prepared using the Quantitect
Reverse Transcription kit (QIAGEN). Primer sets and FAMdye-labeled TaqMan
MGB probes (Eurogentec) were designed for zebrafish fgfr1, fgfr2, fgfr3, fgfr4,
and b-actin genes, and PCR reactions were carried out on a 7500 Fast Real-
time PCR system (ABI). Each sample was analyzed in triplicate along with
specific standards and no template controls. Amplifications were carried out
using 23 TaqMan Universal PCR Master Mix, 203 Assays-on-demand Gene
Expression Assay Mix. Calculations of the initial mRNA copy numbers in
each sample were made according to the cycle threshold (CT) method. The
copy numbers of fgfr1, fgfr2, fgfr3, fgfr4, mRNA were normalized using b-actin
mRNA levels. No significant differences were observed between treatment
groups in the b-actin mRNA levels.
HPLC Quantification
Zebrafish tissues were triturated in pure water by pipetting up and down. The
protein concentration was determined using the BCA assay (Thermo Fisher);
150 ml of acetonitrile was subsequently added to 100 ml of biological sample,
thereby denaturing the proteins. The sample was then centrifuged for 10 min
at 14,100 g in an Eppendorf Minispin Plus (Eppendorf AG, Hamburg). After
centrifugation, the supernatant was transferred to another recipient and centri-
fuged again for 10 min at 14,100 g. The final supernatant was then transferred
into a vial for injection.
In an attempt to estimate the tissue concentration of SSR in an intact zebra-
fish embryo, we measured the dimensions of 45 hpf embryos (3 mm long 3
1.5 mm high 3 1.5 mm wide) and estimated its volume to be 6.75 mm3.
When using a previously established HPLCmethod (Bono et al., 2013; Herbert
et al., 2013) andmeasuring the protein content of each sample, we determined
the corresponding tissue concentration range of SSR (expressed in mg/mg
protein or in mM) for various SSR concentrations added to the swimming water
(Table S1). This resulted in tissue concentrations of SSR ranging from 5 to
47 mM, respectively. Taking into account that only <2% of SSR is not bound
to (plasma) proteins and is thus bioavailable (Bono et al., 2013), tissue concen-
trations of SSR in zebrafish embryos, exposed to SSR concentrations in the
swimming water varying between 10 to 200 mM, were thus estimated to vary
between 100 nM and 1 mM. Even though these values are only estimates
at best, these concentrations of free SSR in zebrafish embryos are comparable
to those observed in mouse plasma (200–800 nM), as well as to the concentra-
tions affecting EC responses in vitro (Bono et al., 2013).
Statistics
All data represent the mean ± SEM of the indicated number of experiments.
We used Prism 6 for statistical calculations. Statistical significance was1316 Chemistry & Biology 21, 1310–1317, October 23, 2014 ª2014 Ecalculated by the indicated test, considering p < 0.05 as statistically
significant.
Animal Experiments
All procedures and care of animals were approved by the Institutional Animal
Care and Research Advisory Committee (KU Leuven, Belgium) and all animal
experiments were performed in accordance with the institutional and national
guidelines and regulations.
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Supplemental Information includes one figure, one table, and two movies and
can be found with this article online at http://dx.doi.org/10.1016/j.chembiol.
2014.07.018.
ACKNOWLEDGMENTS
F.D. and F.C. are supported by the Fund for Scientific Research (FWO), Flan-
ders. This work is supported by grant #G.0789.11 and #G.0764.10 from the
FWO, Belgium; the Belgian Science Policy (IAP #P7/03); Leducq Network of
Excellence (ARTEMIS); and long-term structural Methusalem funding by the
Flemish Government to P.C. P.C. and and F.D. are inventors on the interna-
tional patent application ‘‘extracellular allosteric inhibitor binding domain
from a tyrosine kinase receptor’’ with publication number WO2011/001413
and its national counterparts.
Received: November 3, 2013
Revised: June 26, 2014
Accepted: July 14, 2014
Published: September 4, 2014
REFERENCES
Arman, E., Haffner-Krausz, R., Chen, Y., Heath, J.K., and Lonai, P. (1998).
Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests
a role for FGF signaling in pregastrulation mammalian development. Proc.
Natl. Acad. Sci. USA 95, 5082–5087.
Basham, K.J., Kieffer, C., Shelton, D.N., Leonard, C.J., Bhonde, V.R.,
Vankayalapati, H., Milash, B., Bearss, D.J., Looper, R.E., and Welm, B.E.
(2013). Chemical genetic screen reveals a role for desmosomal adhesion
in mammary branching morphogenesis. J. Biol. Chem. 288, 2261–2270.
Bayliss, P.E., Bellavance, K.L., Whitehead, G.G., Abrams, J.M., Aegerter, S.,
Robbins, H.S., Cowan, D.B., Keating, M.T., O’Reilly, T., Wood, J.M., et al.
(2006). Chemical modulation of receptor signaling inhibits regenerative
angiogenesis in adult zebrafish. Nat. Chem. Biol. 2, 265–273.
Bellou, S., Pentheroudakis, G., Murphy, C., and Fotsis, T. (2013). Anti-angio-
genesis in cancer therapy: Hercules and hydra. Cancer Lett. 338, 219–228.
Bendfeldt, K., Radojevic, V., Kapfhammer, J., and Nitsch, C. (2007). Basic
fibroblast growth factor modulates density of blood vessels and preserves
tight junctions in organotypic cortical cultures of mice: a new in vitro model
of the blood-brain barrier. J. Neurosci. 27, 3260–3267.
Blum, Y., Belting, H.G., Ellertsdottir, E., Herwig, L., Lu¨ders, F., and Affolter, M.
(2008). Complex cell rearrangements during intersegmental vessel sprouting
and vessel fusion in the zebrafish embryo. Dev. Biol. 316, 312–322.
Bono, F., De Smet, F., Herbert, C., De Bock, K., Georgiadou, M., Fons, P.,
Tjwa, M., Alcouffe, C., Ny, A., Bianciotto, M., et al. (2013). Inhibition of tumor
angiogenesis and growth by a small-molecule multi-FGF receptor blocker
with allosteric properties. Cancer Cell 23, 477–488.
Casanovas, O., Hicklin, D.J., Bergers, G., and Hanahan, D. (2005). Drug
resistance by evasion of antiangiogenic targeting of VEGF signaling in late-
stage pancreatic islet tumors. Cancer Cell 8, 299–309.
Charron, F., and Tessier-Lavigne, M. (2005). Novel brain wiring functions
for classical morphogens: a role as graded positional cues in axon guidance.
Development 132, 2251–2262.
Chittenden, T.W.,Claes, F., Lanahan,A.A., Autiero,M., Palac, R.T., Tkachenko,
E.V., Elfenbein, A., Ruiz de Almodovar, C., Dedkov, E., Tomanek, R., et al.lsevier Ltd All rights reserved
Chemistry & Biology
Role for FGF Signaling in Blood Vessel Maintenance(2006). Selective regulation of arterial branching morphogenesis by synectin.
Dev. Cell 10, 783–795.
Crawford, Y., and Ferrara, N. (2009). VEGF inhibition: insights from preclinical
and clinical studies. Cell Tissue Res. 335, 261–269.
Fabian, M.A., Biggs, W.H., 3rd, Treiber, D.K., Atteridge, C.E., Azimioara, M.D.,
Benedetti, M.G., Carter, T.A., Ciceri, P., Edeen, P.T., Floyd, M., et al. (2005).
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat.
Biotechnol. 23, 329–336.
Ferrara, N., and Kerbel, R.S. (2005). Angiogenesis as a therapeutic target.
Nature 438, 967–974.
Geudens, I., Herpers, R., Hermans, K., Segura, I., Ruiz de Almodovar, C.,
Bussmann, J., De Smet, F., Vandevelde, W., Hogan, B.M., Siekmann, A.,
et al. (2010). Role of delta-like-4/Notch in the formation and wiring of the
lymphatic network in zebrafish. Arterioscler. Thromb. Vasc. Biol. 30, 1695–
1702.
Ghabrial, A., Luschnig, S., Metzstein, M.M., and Krasnow, M.A. (2003).
Branching morphogenesis of the Drosophila tracheal system. Annu. Rev.
Cell Dev. Biol. 19, 623–647.
Hatanaka, K., Lanahan, A.A., Murakami, M., and Simons, M. (2012). Fibroblast
growth factor signaling potentiates VE-cadherin stability at adherens junctions
by regulating SHP2. PLoS ONE 7, e37600.
Hausott, B., Rietzler, A., Vallant, N., Auer, M., Haller, I., Perkhofer, S., and
Klimaschewski, L. (2011). Inhibition of fibroblast growth factor receptor 1 endo-
cytosis promotes axonal branching of adult sensory neurons. Neuroscience
188, 13–22.
Herbert, C., Schieborr, U., Saxena, K., Juraszek, J., De Smet, F., Alcouffe, C.,
Bianciotto, M., Saladino, G., Sibrac, D., Kudlinzki, D., et al. (2013). Molecular
mechanism of SSR128129E, an extracellularly acting, small-molecule, allo-
steric inhibitor of FGF receptor signaling. Cancer Cell 23, 489–501.
Huang, C.C., Lawson, N.D., Weinstein, B.M., and Johnson, S.L. (2003). reg6
is required for branching morphogenesis during blood vessel regeneration in
zebrafish caudal fins. Dev. Biol. 264, 263–274.
Itoh, N., and Ornitz, D.M. (2011). Fibroblast growth factors: from molecular
evolution to roles in development, metabolism and disease. J. Biochem.
149, 121–130.
Jain, R.K., Duda, D.G., Clark, J.W., and Loeffler, J.S. (2006). Lessons from
phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract.
Oncol. 3, 24–40.
Javerzat, S., Auguste, P., and Bikfalvi, A. (2002). The role of fibroblast growth
factors in vascular development. Trends Mol. Med. 8, 483–489.
Jeltsch, M., Leppa¨nen, V.M., Saharinen, P., and Alitalo, K. (2013). Receptor
tyrosine kinase-mediated angiogenesis. Cold Spring Harb. Perspect. Biol. 5,
a009183.
Jin, S.W., Beis, D., Mitchell, T., Chen, J.N., and Stainier, D.Y. (2005). Cellular
and molecular analyses of vascular tube and lumen formation in zebrafish.
Development 132, 5199–5209.
Lavine, K.J., White, A.C., Park, C., Smith, C.S., Choi, K., Long, F., Hui, C.C.,
and Ornitz, D.M. (2006). Fibroblast growth factor signals regulate a wave of
Hedgehog activation that is essential for coronary vascular development.
Genes Dev. 20, 1651–1666.Chemistry & Biology 21, 1310–1Lawson, N.D., and Weinstein, B.M. (2002). In vivo imaging of embryonic
vascular development using transgenic zebrafish. Dev. Biol. 248, 307–318.
Lee, S.H., Schloss, D.J., and Swain, J.L. (2000). Maintenance of vascular
integrity in the embryo requires signaling through the fibroblast growth factor
receptor. J. Biol. Chem. 275, 33679–33687.
Lemmon, M.A., and Schlessinger, J. (2010). Cell signaling by receptor tyrosine
kinases. Cell 141, 1117–1134.
Liang, G., Chen, G., Wei, X., Zhao, Y., and Li, X. (2013). Small molecule inhibi-
tion of fibroblast growth factor receptors in cancer. Cytokine Growth Factor
Rev. 24, 467–475.
Malemud, C.J. (2007). Growth hormone, VEGF and FGF: involvement in rheu-
matoid arthritis. Clin. Chim. Acta 375, 10–19.
Miller, D.L., Ortega, S., Bashayan, O., Basch, R., and Basilico, C. (2000).
Compensation by fibroblast growth factor 1 (FGF1) does not account for
the mild phenotypic defects observed in FGF2 null mice. Mol. Cell. Biol. 20,
2260–2268.
Murakami, M., Nguyen, L.T., Zhang, Z.W., Moodie, K.L., Carmeliet, P., Stan,
R.V., and Simons, M. (2008). The FGF system has a key role in regulating
vascular integrity. J. Clin. Invest. 118, 3355–3366.
Murakami, M., Nguyen, L.T., Hatanaka, K., Schachterle, W., Chen, P.Y.,
Zhuang, Z.W., Black, B.L., and Simons, M. (2011). FGF-dependent regulation
of VEGF receptor 2 expression in mice. J. Clin. Invest. 121, 2668–2678.
Poss, K.D., Shen, J., Nechiporuk, A., McMahon, G., Thisse, B., Thisse, C., and
Keating, M.T. (2000). Roles for Fgf signaling during zebrafish fin regeneration.
Dev. Biol. 222, 347–358.
Potente, M., Gerhardt, H., and Carmeliet, P. (2011). Basic and therapeutic
aspects of angiogenesis. Cell 146, 873–887.
Reifers, F., Walsh, E.C., Le´ger, S., Stainier, D.Y., and Brand, M. (2000).
Induction and differentiation of the zebrafish heart requires fibroblast growth
factor 8 (fgf8/acerebellar). Development 127, 225–235.
Ribatti, D., and Presta, M. (2002). The role of fibroblast growth factor-2 in the
vascularization of the chick embryo chorioallantoic membrane. J. Cell. Mol.
Med. 6, 439–446.
Saylor, P.J., Escudier, B., and Michaelson, M.D. (2012). Importance of
fibroblast growth factor receptor in neovascularization and tumor escape
from antiangiogenic therapy. Clin. Genitourin. Cancer 10, 77–83.
Sekine, K., Ohuchi, H., Fujiwara, M., Yamasaki, M., Yoshizawa, T., Sato, T.,
Yagishita, N., Matsui, D., Koga, Y., Itoh, N., and Kato, S. (1999). Fgf10 is
essential for limb and lung formation. Nat. Genet. 21, 138–141.
Szebenyi, G., Dent, E.W., Callaway, J.L., Seys, C., Lueth, H., and Kalil, K.
(2001). Fibroblast growth factor-2 promotes axon branching of cortical neu-
rons by influencing morphology and behavior of the primary growth cone.
J. Neurosci. 21, 3932–3941.
Tole, S., Gutin, G., Bhatnagar, L., Remedios, R., and He´bert, J.M. (2006).
Development of midline cell types and commissural axon tracts requires
Fgfr1 in the cerebrum. Dev. Biol. 289, 141–151.
Zhou, M., Sutliff, R.L., Paul, R.J., Lorenz, J.N., Hoying, J.B., Haudenschild,
C.C., Yin, M., Coffin, J.D., Kong, L., Kranias, E.G., et al. (1998). Fibroblast
growth factor 2 control of vascular tone. Nat. Med. 4, 201–207.317, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1317
